The next big thing in the weight loss drug boom has little to do with losing weightByBruce GilPublishedJuly 15, 2024
Ozempic and other weight loss drugs pose new risks for surgery, Europe warnsByBruce GilPublishedJuly 12, 2024
Pfizer's weight loss pill, Novo Nordisk's setback, and the FTC vs. drug middlemen: Pharma news roundupByBruce GilUpdatedJuly 12, 2024
Novo Nordisk's once-weekly insulin is rejected by the FDA, in latest set back for the pharma giantByBruce GilPublishedJuly 11, 2024
Pfizer says it is advancing development of a once-daily weight loss pillByBruce GilPublishedJuly 11, 2024
Patients taking Ozempic for weight loss typically stop using it within 2 years, analysis findsByBruce GilPublishedJuly 10, 2024
Purdue Pharma's Sackler family could face $1 trillion in damages if a second settlement failsByBen KesslenPublishedJuly 9, 2024
Drug middlemen are hiking the price of cancer drugs and reaping huge profits, FTC saysByBen KesslenPublishedJuly 9, 2024
Eli Lilly's Mounjaro is more effective at weight loss than Novo Nordisk's Ozempic and Wegovy, study findsByBruce GilPublishedJuly 9, 2024
Ozempic and other GLP-1 drugs could reduce risk of cancer for diabetes patients, study saysByBruce GilPublishedJuly 5, 2024
Ozempic could be linked to a common cause of sudden blindness, study saysByBruce GilPublishedJuly 3, 2024
A Wegovy ad was the third most seen television commercial this past JuneByBruce GilPublishedJuly 2, 2024
Eli Lilly is one step closer to gaining access to one of the world's largest weight loss marketsByBruce GilPublishedJuly 1, 2024
A group of cancer victims couldn't block Johnson & Johnson's $6.5 billion talc-powder settlementByBruce GilUpdatedJuly 1, 2024
Novo Nordisk will restrict Wegovy sales in China amid a weight loss drug shortageByBruce GilUpdatedJune 27, 2024
Now playing Ozempic maker Novo Nordisk just got access to one of the world's largest weight loss marketsByBruce GilPublishedJune 25, 2024
